What is Dermisonics Inc?
manufactures ultrasonic transdermal drug-delivery technologies and equipment.
DMSI · Verdict
Moderate reward · elevated risk
DMSI stands out on volatility and balance sheet, but watch the cash flow signal.
Based on 88% data coverage
DMSI · Verdict
Above average
Current ratio 0.14
Weak vs peers
-392% return on equity
Earnings +295.0% CAGR
Model-based scoring. For information only — not financial advice.
manufactures ultrasonic transdermal drug-delivery technologies and equipment. It primarily focuses on the development, testing, and commercialization of its active transdermal patch, called the U-Strip, that has been designed to facilitate the needle-free delivery of drugs with large molecular structures, such as Insulin into the bloodstream. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 1.92K.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.